Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19.

Cristina Lavilla OllerosCristina Ausín GarcíaAlejandro David Bendala EstradaAna MuñozPhilip Erick Wikman JogersenAna Fernández CruzVicente Giner GalvañJuan Antonio VargasJosé Miguel Seguí RipollManuel Rubio-RivasRodrigo Miranda GodoyLuis Mérida RodrigoEva Fonseca AizpuruFrancisco Arnalich FernándezArturo ArteroJose Loureiro AmigoGema María García García Luis Corral Gudino Jose Jiménez TorresJosé-Manuel Casas-RojoJesús Millán Núñez-Cortésnull null

Published in: PloS one (2022)

There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses.

Keyphrases

low dose
risk factors
coronavirus disease
sars cov
respiratory syndrome coronavirus
cardiovascular events
high dose
type diabetes
cardiovascular disease
coronary artery disease